HPV :: Transgene & Roche Partnership on HPV Vaccines

Roche and Transgene S.A. announced that they have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from Transgene’s therapeutic vaccine program against Human Papilloma Virus-mediated diseases.

The Human Papilloma Virus (HPV) is associated with the development of precancerous lesions and cancer of the cervix.

The agreement includes Transgene’s lead therapeutic vaccine candidate TG 4001 (MVA-HPV-IL2), currently in clinical development to treat high grade cervical intraepithelial neoplasia (CIN2/3), a precancerous cervical abnormality which can lead to cervical cancer. Under the agreement, Roche will lead worldwide development and commercialization. TG 4001 has completed Phase II studies and is in planning for entry into Phase III studies.

‘We are delighted by Roche’s commitment to further develop our promising vaccine TG 4001 in the field of HPV-mediated diseases,’ said Philippe Archinard, Chief Executive Officer of Transgene. ‘Roche has broad expertise and a leadership position in the development and marketing of first-in-class innovative therapies. This first strategic partnership is an acknowledgement of the validity of our technology and strategy. It is a considerable transforming event for Transgene that we anticipate will enable us to accelerate and broaden the development of our entire product portfolio.’

‘Transgene is an ideal strategic fit for Roche, offering a differentiated approach to a precancerous condition with high unmet need,’ said Peter Hug, Roche’s Global Head of Pharma Partnering. ‘Transgene’s expertise in viral vaccine therapeutics complements our core capabilities in oncology and virology drug development. In addition, as Roche is a leader in in vitro diagnostics with strong capabilities in HPV detection, our collaboration with Transgene has the potential to expand and evolve into an integrated personalized medicine approach. We look forward to working with Transgene on this program.’


Leave a Comment